Epithelial-to-mesenchymal transdifferentiation (EMT) mediated by transforming growth factor-b (TGF-b) signaling leads to aggressive cancer progression. In this study, we identified zinc-a2-glycoprotein (AZGP1, ZAG) as a tumor suppressor in pancreatic ductal adenocarcinoma whose expression is lost due to histone deacetylation. In vitro, ZAG silencing strikingly increased invasiveness of pancreatic cancer cells accompanied by the induction of a mesenchymal phenotype. Expression analysis of a set of EMT markers showed an increase in the expression of mesenchymal markers (vimentin (VIM) and integrin-a5) and a concomitant reduction in the expression of epithelial markers (cadherin 1 (CDH1), desmoplakin and keratin-19). Blockade of endogenous TGF-b signaling inhibited these morphological changes and the downregulation of CDH1, as elicited by ZAG silencing. In a ZAG-negative cell line, human recombinant ZAG (rZAG) specifically inhibited exogenous TGF-b-mediated tumor cell invasion and VIM expression. Furthermore, rZAG blocked TGF-b-mediated ERK2 phosphorylation. PCR array analysis revealed that ZAG-induced epithelial transdifferentiation was accompanied by a series of concerted cellular events including a shift in the energy metabolism and prosurvival signals. Thus, epigenetically regulated ZAG is a novel tumor suppressor essential for maintaining an epithelial phenotype.
Introduction
Zinc-a2-glycoprotein (AZGP1, ZAG) is a secreted 41-kDa protein whose function has not yet been fully elucidated. ZAG has initially been identified and purified in human serum already in 1961 (Burgi and Schmid, 1961) . Using immunohistochemical studies, it has been found that ZAG is expressed mainly in epithelial cells of the breast, the prostate, the liver and various other gastrointestinal organs (Tada et al., 1991) . In line with its production by secretory epithelial cells, ZAG is found in a number of body fluids (Frenette et al., 1987; Ohkubo et al., 1990) . Recently, it has been shown that ZAG might be involved in carcinogenesis and tumor differentiation. Thus, in prostate and breast cancer, expression of ZAG has been linked to poorer tumor differentiation (Diez-Itza et al., 1993; Hale et al., 2001 ) though the underlying mechanisms remain elusive. ZAG has also been associated with cancer cachexia due to its high level of amino-acid sequence homology with tumor-derived lipid-mobilizing factor (Russell et al., 2004) and because in a mouse model of ZAG-producing tumors, ZAG stimulated lipolysis in adipocytes leading to cachexia (Bing et al., 2004) .
Epithelial-to-mesenchymal transdifferentiation (EMT) leading to aggressive cancer progression is considered to be a crucial event in the carcinogenesis of pancreatic ductal adenocarcinoma (PDAC). EMT is characterized by the loss of epithelial characteristics and by the acquisition of a mesenchymal phenotype (Brabletz et al., 2005) . During carcinogenesis and development of a more mesenchymal phenotype, less motile (epithelial) cells restart developmental programs (that is, transforming growth factor-b (TGF-b), notch, Wnt and hedgehog pathways) to gain migratory and invasive properties (Ellenrieder et al., 2001; Brabletz et al., 2005; Dembinski and Krauss, 2009; Wang et al., 2009) . This involves the loss of cell-cell junctions and a reorganization of the actin cytoskeleton, as well as the acquisition of resistance to apoptosis, and thus of resistance to chemotherapy (Robson et al., 2006; Wang et al., 2009) . The complexity of the underlying signaling processes and the adoption of a completely different phenotype imply that EMT is not a simple change in migratory/invasive capabilities but rather a switch into a different cellular program. Importantly, these 'features' seem to necessitate that the cell forfeits proliferative capacities to survive under anchorage-independent conditions, as recently shown in K-ras/extracellular signal-regulated kinase (ERK)-activated breast cancer cells (Evdokimova et al., 2009) . Similarly in pancreas cancer, a subpopulation of slowly dividing cancer cells show an EMT-resembling morphology (Dembinski and Krauss, 2009) . On the molecular level, EMT is defined by downregulation of epithelial differentiation markers (for example, cadherin 1 (CDH1)) and by the transcriptional induction of mesenchymal markers, such as vimentin (VIM) and CDH2. In spite of its high activation threshold, EMT can be induced by members of the TGF-b family including TGF-b1 and BMP4 (Ellenrieder et al., 2001; Hamada et al., 2007) . Though TGF-b is a tumor suppressor in the early stages of PDAC, it contributes to tumor progression by promoting EMT and invasion in the late cancer stages (Ellenrieder et al., 2001; Hamada et al., 2007) . Constitutively active Ras signaling-as a consequence of Kras mutations that are present in 70-90% of PDAChas been shown to be indispensable for TGF-b-mediated induction of EMT (Longnecker and Terhune, 1998; Ellenrieder et al., 2001; Roberts and Wakefield, 2003; Horiguchi et al., 2009) . These data suggest that TGF-b cooperates with Ras/ERK signaling in advanced stages of PDAC promoting invasion and metastasis through EMT. Therefore, EMT not only entails the orchestration of promigratory/invasive events but also reorganization of proliferation to allow for survival in different microenvironments. As we show ZAG to be widely lost in pancreatic cancer, we hypothesize that it might have tumor-suppressor functions and that it might be involved in EMT in PDAC.
Results
Expression of ZAG is decreased in primary and metastatic PDAC Quantitative real-time-PCR (QRT-PCR) of bulk normal pancreatic tissues (n ¼ 19) and PDAC (n ¼ 57) tissues revealed a significant downregulation of ZAG mRNA expression in PDAC (À6.5 Â , Po0.0001; Figure 1a ). Though ZAG staining was predominantly detected in acinar and peripheral cells of islets in the normal pancreas (Figure 1b) , its expression in normal ducts was generally absent (Supplementary Figure 1) . In contrast, ZAG staining in cancer cells was lost in 74% of the PDAC cases (42/57) and only 21% (12/57) and 5% (3/57) of the samples showed moderate or strong ZAG staining intensities in cancer cells (Figure 1c, right panel) . Consistent with our results, published serial analysis of gene expression data of isolated primary PDAC cells demonstrated that 50% (12/24) of cancers showed low expression of ZAG (less than 100 tags), whereas 37.5% (9/24) and 12.5% (3/24) of the cells expressed moderate (100-1000 tags) or high (more than 1000 tags) ZAG levels (Jones et al., 2008;  Figure 1c , left panel; http://www.sciencemag.org/cgi/content/full/sci; 1164368/DC1). Moreover, 39 metastatic PDAC tissues consisting of liver metastasis (23), lymph node metastasis (6), peritoneal metastasis (6), omentum metastasis (3) and muscle metastasis (1) were stained for ZAG.
Among these samples we detected, apart from two (5%) ZAG-positive liver metastases (Figure 1d , right lower panel), only ZAG-negative (Figure 1d ) metastatic cancer cells. In addition, ZAG staining was performed on a tissue Pancreatic Intraepithelial Neoplasia (PanIN) array containing 44 PanIN lesions of different grades. It is of note that scattered ZAG-expressing cells were observed in 48% (21/44) of the lesions, though the appearance of such scattered ZAG-positive cells was not correlated to the grade of the lesions (Figure 1e) . Comparison of the staining intensities in PanIN lesions, primary and metastatic PDAC revealed striking differences in expression levels ( Figure 1f , 48 vs 26 vs 5%, Po0.05). As ZAG expression was mainly observed in acinar and endocrine cells in the normal pancreas, we set out to investigate its expression in pancreatic endocrine tumors (PETs) and in acinar cell carcinomas (ACCs). Although ZAG expression was detected in 50% (7/14) of the PET samples and two out of three PET cell lines ( Supplementary Figures 2A and B) , only 18% (2/11) of the ACC samples were positive for ZAG (Supplementary Figure 2C ). Altogether, the rate of ZAG-positive cancer cells in PET was generally higher than that in PDAC and ACC (Figure 1g , 50 vs 26 and 18%).
Few cancer cell lines express and secrete ZAG ZAG mRNA expression and ZAG protein (cell lysates and supernatants) were only found in two (Aspc-1 and Capan-1) out of seven tested cell lines (Aspc-1, Capan-1, Colo-357, Mia-PaCa-2, Panc-1, T3M4 and Su86.86; Figures 2a and b) . As there are three N-linked glycosylation sites on human ZAG (as assessed by X-ray crystallography) (Ohkubo et al., 1990; Rolli et al., 2007) , we set out to determine whether glycosylation contributes to cellular transport of ZAG. In line with this assumption, inhibition of N-linked glycosylation by tunicamycin significantly decreased ZAG secretion in Aspc-1 and Capan-1 cells (Figure 2c ). Though there were no differences between ZAG expression and secretion in cancer cell lines, we hypothesized that secretion might be altered in vivo (potentially due to deglycosylation). Therefore, we measured ZAG levels in the sera of PDAC patients (n ¼ 16) and healthy volunteers (n ¼ 14) revealing no significant differences between the groups (Figure 2d ).
Histone deacetylase inhibition reconstitutes ZAG expression and induces MET in pancreatic cancer cells To assess the mechanism underlying downregulation/ loss of ZAG in most of the tested PDAC cells, we performed demethylation and deacetylation-inhibition assays. Although the histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) reconstituted ZAG expression in the two ZAG-negative cell lines T3M4 and Panc-1 on both the mRNA and protein levels (Figures 3a and b) , demethylation using 5-aza-2 0 -deoxycytidine (5-aza) had no such effect (data not shown). Similar results were also obtained from two additional cell lines ), though to a lesser extent than in Su86.86 cells (Supplementary (Jones et al., 2008) : 50% of primary PDAC cells express low levels of ZAG, whereas 37.5 and 12.5% show moderate and high ZAG expression levels, respectively (left panel, http://www.sciencemag.org/cgi/content/full/sci;1164368/DC1). In the majority (74%) of the analyzed primary PDAC tissue sections, cancer cells are ZAG-negative, whereas 21 and 5% exhibit weak and strong staining of ZAG, respectively (right panel, 
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B Kong et al Figures 3A and B) . We corroborated these findings by treating Panc-1 cells with TSA, which induced a timedependent, increased acetylation of histone H3 (Figure 3c ). Chromatin immunoprecipitation revealed a significantly increased binding of acetylated histone H3 to the ZAG promoter (Figure 3d) , suggesting an open chromatin conformation within that region. As it has been shown recently that inhibition of HDAC in Panc-1 cells abolished TGF-b1-mediated EMT (Fritsche et al., 2009; von Burstin et al., 2009) Figure 3e ). The changes in CDH1 and VIM expression were also confirmed on the protein level ( Figure 3f ). Consistently, TSA treatment significantly decreased cancer cell invasion ( Figure 3g , upper panel), whereas no influence on cell proliferation was observed ( Figure 3g , lower panel). Figure 4A ). However, RNAi-mediated ZAG silencing strikingly increased invasiveness of Aspc-1 cells, which was partially reversible by treatment with rZAG (though to a lesser extent when using lower concentrations of rZAG; Figure 4a , right panel). As this increase in invasiveness was accompanied by significant phenotypic changes of cellular morphology ( Figure 4b , left panel; more epithelial structure of control cells vs a fibroblast-like phenotype of many siRNA-treated cells forming scattered cell clusters; confirmed by actin staining, Figure 4b ), we hypothesized that ZAG RNAi might induce a mesenchymal program. Therefore, we performed QRT-PCR to the compare expression patterns of a panel of EMT markers (CDH1, KRT19, DSP, VIM, ITGA5, ITGB1, ITGAV and ITGA3) between control and ZAG-silenced Aspc-1 cells. This assay revealed that the epithelial markers CDH1, DSP and KRT19 were significantly downregulated whereas the mesenchymal markers VIM and ITGA5 were upregulated ( Figure 4b , middle panel). The changes in CDH1 and VIM expression were confirmed at the protein level ( Figure 4b , right panel). In addition, we validated the results of the invasion assays as well as the changes in morphology and EMT markers using two ZAG siRNA molecules (Supplementary Figures 4B and C) . Because TGF-b signaling is considered to be one of the major driving forces of EMT in PDAC, we speculated that the inhibitory effect of ZAG on EMT might be attributed to a (direct/indirect) blockade of endogenous TGF-b signaling. Furthermore, it has recently been shown that in Smad4-deficient pancreatic cancer cell lines, autocrine activation of the TGF-b receptor system occurs (Subramanian et al., 2004) . As Aspc-1 cells are Smad4 negative due to a point mutation (Wan et al., 2005) , we selectively inhibited type I TGF-b receptor/ALK5 (SB525354) and both type I and type II TGF-b receptors (LY364847) after having silenced ZAG. Though ALK5/type I TGF-b receptor blockade by SB525354 had no effect, the combined inhibition of type I and type II TGF-b receptors by LY364847 reversed the morphological changes elicited by ZAG silencing ( Figure 4c , left panel). Furthermore, LY364847 treatment alone induced upregulation of CDH1 confirming an important role of endogenous TGF-b in Although TGF-b1 time-dependently induced phosphorylation of Smad2, neither rZAG alone nor rZAG in combination with TGF-b1 had any additional effect ( Figure 5a ). As exogenous TGF-b1 causes sustained phosphorylation of ERK2, which is essential for TGFb1-mediated EMT (Ellenrieder et al., 2001) , we evaluated ERK2 phosphorylation following treatment with TGF-b1 for 24 h (±rZAG). These assays revealed that the TGF-b1-mediated increase in ERK2 phosphorylation was blocked by preincubation with rZAG ( Figure 5b ). Because TGF-b1-mediated inhibition of cell growth is partially transduced by transcriptional induction of the cell-cycle inhibitor p21(WAF1/Cip1; p21), regulated by Smad4 (Finkel, 1996) , we used p21 as an internal control for the activation of the Smad4-dependent TGF-b pathway. These experiments revealed that in Panc-1 cells with intact Smad4, TGF-b1 treatment induced expression of p21 that remained unchanged by treatment with rZAG ( Figure 5b ), suggesting that rather the cross talk between TGF-b and Ras/ERK signaling than the Smad4-dependent pathway is blocked by rZAG. Accordingly, in Aspc-1 (Smad4-negative) cells, ZAG silencing, as well as TGFb1 treatment, caused sustained phosphorylation of ERK2, presumably due to (facilitation of) activation of endogenous TGF-b signaling (Figure 5c ). Interestingly, ZAG RNAi alone or in combination with TGF-b1 induced p21 expression (Figure 5c ).
ZAG inhibits invasion of pancreatic cancer cells by blocking TGF-b-mediated EMT
ZAG at the crossroads of cellular differentiation and energy control To further characterize signal transduction pathways modulated by ZAG, we used an RT-PCR-based (Figure 6a ). In line with our findings above, BMP4 and CDKN1B were increased, which reflected the activation of endogenous TGF-b signaling (Lecanda et al., 2009 Figures 5A and B) , which is consistent with published results (Ellenrieder et al., 2001; Hamada et al., 2007) . Furthermore, BCL2L1, CCND1 and MYC, which are survival pathway-related genes, were upregulated underscoring the importance of prosurvival signals during EMT (Biliran et al., 2005; Freemantle et al., 2007; Barbie et al., 2009 ). EGR1, which represents a mitogenic pathway, was downregulated, consistent with the observed increased expression of the cell-cycle inhibitor p21 (Lim et al., 2008) . Surprisingly, HK2 and CEBPB, which are insulin-responsive factors, were highly induced after ZAG RNAi. We thus speculate that the increased levels of HK2, which catalyzes one of the first steps in glucose metabolism, reflect an increased demand for glucose 
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(and thus an increased energy need) when cancer cells undergo EMT. Correspondingly, GYS1-an enzyme responsible for adding glucose monomers to glycogenwas downregulated. These results were confirmed by independent QRT-PCR assays (Figure 6b ), and increased expression of HK2 was confirmed on the protein level (Figure 6c ). To interrogate whether HK2 is functionally relevant for EMT and cell invasion, we chose the highly invasive pancreatic cancer cell lines Panc-1 and Su86.86 for further analysis. As expected, HK2 RNAi suppressed HK2 expression in Panc-1 and Su86.86 cells (Figure 6d , lower panel). Though downregulation of HK2 did not significantly affect cell proliferation, it strikingly inhibited cell invasion ( Figure 6d , upper panel; confirmed using another HK2 siRNA; data not shown). However, no changes in the expression of EMT markers after silencing HK2 were observed in Panc-1 and Su86.86 cells (data not shown). These results suggest that a certain level of HK2 or glucose metabolism is essential for maintaining the basal invasiveness of cancer cells rather than their differentiation status. Therefore, we speculate that these molecules cooperatively promote EMT and cell invasion following a loss of ZAG. To conclude, loss of ZAG in Aspc-1 seems not only to induce EMT but to also reprogram the cells within a series of concerted cellular events consisting of increased energy consumption, a prosurvival signal and a lower proliferation rate (Figure 6e ).
Discussion
In K-ras-transformed pancreatic cancer cells, epithelial plasticity and EMT are increasingly seen as epigenetic phenomena (Singh et al., 2009) , which is supported by recent findings in other malignancies, such as breast cancer in which a signal from the tumor microenvironment (for example, TGF-b) can induce phenotypic and gene expression changes associated with de novo epigenetic events important for EMT (Dumont et al., 2008) . In general, methylation (regulated by DNA methyltransferases and histone deacetylation (regulated by HDACs) are two main mechanisms through which epigenetic regulation is conferred (Jaenisch and Bird, 2003; Glozak and Seto, 2007) . By removing acetyl groups from histones, it is found that HDACs create a non-accessible chromatin conformation that reduces the transcription of genes (that is, those which are implicated in the control of cell growth differentiation and apoptosis) (Glozak and Seto, 2007) . In PDAC, HDAC inhibitors have been shown to block cell proliferation to promote differentiation and to induce apoptosis (Fritsche et al., 2009; Von Burstin et al., 2009) ; we showed that TSA blocks cell invasion and promotes mesenchymal-to-epithelial transdifferentiation (MET) in human PDAC cells, therefore, these might constitute promising anticancer agents-given that gene-specific control would be possible. The link between the epigenetic HDAC machinery, EMT and metastasis has also recently been shown using highly metastatic (mesenchymal phenotype) cancer cells derived from a genetically engineered mouse pancreas cancer model; in these cells, silencing of CDH1 was mediated by a transcriptional repressor complex containing snail, HDAC1 and HDAC2 (von Burstin et al., 2009) . In our study, we now show that the expression of ZAG-an EMT related gene-is also lost due to histone deacetylation. However, because validated siRNA transfection against HDAC1-7 failed to significantly reconstitute ZAG expression in Panc-1 cells (data not shown), we hypothesize that a so far unknown corepressor or repressor complex exists. Using a set of in vitro experiments, we showed that ZAG specifically blocks signaling between TGF-b and Ras/ERK. Overexpression of TGF-b ligands and their receptors as well as activating mutations of K-Ras occurs at a very high frequency in PDAC and interactions of these two major pathways have been shown to be crucial in pancreatic carcinogenesis (Lemoine et al., 1992; Friess et al., 1993) . In addition, the Ras/ERK cascade has been shown to be activated by members of the TGF-b family contributing to TGF-b-mediated effects, such as EMT (Ellenrieder et al., 2001; Horiguchi et al., 2009) . The TGF-b signal transducers Smad2 and Smad3 have also been shown to be phosphorylated by ERK (de Caestecker et al., 1998; Kretzschmar et al., 1999) . Recent studies revealed that ERK2 phosphorylation through TGF-b, which occurs in a Ras-dependent way, is essential for TGF-bmediated EMT (Ellenrieder et al., 2001; Horiguchi et al., 2009) . At the same time, it is important to consider that activating K-Ras mutations in the pancreatic cancer cells do not result in constitutively increased ERK signaling (Giehl et al., 2000) . Interestingly, in a mouse colorectal cancer model, the K-Ras tumor phenotype was associated with an attenuated signaling through the mitogen-activated protein kinase pathway (Haigis et al., 2008) . Thus, it is still not clear whether, due to relatively 'low' levels of basal Ras/ERK activity, the threshold of activation of this pathway (that is, by TGF-b) is also relatively low. In our study, we showed that TGF-b1-mediated ERK2 phosphorylation was blocked by ZAG and that this effect was associated with EMT and an increased invasive potential of two pancreatic cancer cell lines, which carry the constitutively active Ras mutation. ZAG seems to function like a specific barrier that interrupts TGF-b/ERK signaling. We further identified (http://scansite.mit.edu) the growth factor receptor-binding protein, 2-Src homology 2 (Grb2-SH2, TLKDIVEYYNDSNGS) domain, within the ZAG sequence. The Grb2-SH2 domain has been described as docking site for activated receptors and, therefore, is important in the oncogenic Ras signal transduction pathway (Lung and Tsai, 2003; Benfield et al., 2007) . We thus speculate that ZAG might exert its effect on TGF-b and Ras/ERK signaling through the Grb2-SH2 domain. However, a synthesized small peptide including this region failed to reconstitute the function of the full-length protein in our experimental setup (data not shown), adding another layer of complexity to the underlying mechanism. Nevertheless, AZGP1 in pancreatic cancer B Kong et al the exact molecular mechanisms deserve (and require) further investigation. Though obesity and insulin resistance are potential risk factors for developing pancreatic cancer (Michaud et al., 2001; Calle et al., 2003) , the underlying molecular mechanisms remain elusive. A recent study revealed that high-fat-diet-induced obesity in mice accelerated the development of PanIN in the context of embryonic KRas activation through changes in energy metabolism. These data suggested changes in energy metabolism rather than insulin resistance as key elements in early carcinogenesis of PDAC (Khasawneh et al., 2009) . Recent evidence has also established a link between low serum levels of ZAG and obesity in humans; however, whether ZAG serum levels are also related to insulin resistance is still under debate (Marrades et al., 2008) . Nonetheless, the antidiabetic properties of human ZAG have recently been shown in type 2 diabetes in the ob/ob mouse model (Russell and Tisdale, 2010) . Furthermore, ZAG-deficient animals fed by a standard or a lipid-rich diet were heavier than wild-type mice (Rolli et al., 2007) . Therefore, we hypothesized that ZAG might be involved in early carcinogenetic events in the pancreas through a modulation of energy metabolism pathways. In line with this assumption, silencing of ZAG in PDAC cells lines upregulated the two insulin responsive-factors HK2 and CEBPB, whereas GYS1 levels were decreased. These data suggest that the cancer cells are 'pushed' toward a high-glucose metabolic state that seems to be important for cell invasion. Correspondingly, silencing of HK2 in highly invasive cancer cells strikingly attenuated their invasiveness, which further underscores an essential role of energy metabolism in cellular invasion events. Moreover, such a shift in energy metabolism occurs distinctively within EMT. Though our study is limited by in vitro tissue culture conditions with supraphysiological levels of glucose, oxygen and growth factors, it seems possible that ZAG might serve as a critical mediator adjusting energy metabolism according to the differentiation status of cancer cells. Because cancer cells consume glucose at an accelerated rate with reduced oxidative phosphorylation even in the presence of oxygen (known as the 'Warburg effect'), such a capacity confers a distinct competitive advantage compared with normal epithelial cells (Mathupala et al., 2006; Christofk et al., 2008) . As a consequence, cancer cells that have undergone EMT-inducing a high-glucose metabolic ratemay have gained further malignant 'advantages' compared with the more epithelial, earlier cancer cell stages. Such advantages may help these cells to migrate or survive under even more unfavorable conditions, that is, in 'new' microenvironments as present after having metastasized to distant organs.
In conclusion, our data provide evidence that ZAG affects the differentiation status of pancreatic cancer by blocking the cross talk between TGF-b and Ras/ERK signaling. EMT elicited by loss of ZAG is accompanied by a series of concerted cellular events including a shift in energy metabolism, prosurvival signals and reduced cell proliferation. We speculate that targeting this cross talk by restoring the function of ZAG might constitute a new rational approach to reduce/reverse EMT in pancreatic cancer.
Materials and methods
Patients and tissue sampling Tissue sampling and processing was performed as previously described (Zhang et al., 2007) . Histological examination was carried out by an experienced pathologist (IE). The use of tissue for this study was approved by the local ethics committees and written informed consent was obtained from the patients before the operation.
Cell culture
Seven pancreatic cancer cell lines-ASPC1, Capan1, Colo357, MiaPaca2, SU86.86, Panc1 and T3M4-were cultured was previously described (Zhang et al., 2007) . PET cell lines were cultured in Dulbecco's modified Eagle's medium (Bon-1 and QGP-1) or RPMI 1640 (CM) cell culture media supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ ml streptomycin at 37 1C, 5% CO 2 . The inhibitor of methylation, 5-aza (5 mM; Sigma-Aldrich, St Louis, MO, USA), and the inhibitor of HDAC, TSA (0.1 and 1 mM; Sigma-Aldrich), were added to proliferating or confluent cells (Panc-1, T3M4, Colo-357 and Su86.86) for 72 and 24 h. Cells were then lysed and processed for total RNA extraction or whole cellular extract preparation as described thereafter. For functional assays, cells were treated with TSA for 72 h, and were then subjected to invasion and proliferation assays in the absence of TSA. For the human recombinant BMP4 (rBMP4) assays, Panc-1 and Su86.86 cells were treated with rBMP4 (100 ng/ml; catalog no. 314-BP/CF; R&D, WiesbadenNordenstadt, Wiesbaden, Germany) in serum-free medium for 6 consecutive days before the extraction of protein.
QRT-PCR
The mRNA extraction, cDNA synthesis and QRT-PCR were performed as described previously (specimens used: normal n ¼ 19; PDAC n ¼ 57) (Michalski et al., 2007a) . Data are presented as relative expression fold. b-Actin and hypoxanthine phosphoribosyltransferase 1 were used as housekeeping genes. Sequences of primers are provided in Supplementary data section.
Immunohistochemistry
Immunohistochemistry was performed using the Dako Envision System (Dako Cytomation GmbH, Hamburg, Germany) as previously described (Michalski et al., 2007b) . In brief, tissue sections or a PanIN array (Esposito et al., 2007) were incubated with rabbit anti-human ZAG polyclonal antibodies (1:500, catalog no. RD181093100; BioVendor, Heidelberg, Germany) at 4 1C overnight followed by incubation with a horseradish-peroxidase-linked goat anti-rabbit antibody (Dako Cytomation GmbH), followed by a reaction with diaminobenzidine and counterstaining with Mayer's hematoxylin. To confirm antibody specificity, we incubated tissue sections in the absence of the primary antibodies with negative control rabbit or mouse IgG. Under these conditions, no immunostaining was detected.
Immunofluorescence
Immunofluorescence was performed as previously described (Michalski et al., 2008) . In brief, cytoskeleton actin was labeled AZGP1 in pancreatic cancer B Kong et al with Alexa Fluor 488 phalloidin (Molecular Probes, Eugene, OR, USA). The sections were subsequently mounted with DAPI and antifading medium (Gel/mount; Abcam, Cambridge, UK).
Serum collection and enzyme-linked immunosorbent assay
The serum collection and enzyme-linked immunosorbent assay were performed as previously described (Zhang et al., 2007) . The study was approved by the ethics committee of the University of Heidelberg and written informed consent was obtained from all individuals from whom serum samples were collected. In brief, rabbit anti-ZAG antibody (0.05 mg/ml, catalog no. sc-11358; Santa Cruz Biotechnology, Santa-Cruz, CA, USA) was used as the capture antibody and mouse anti-ZAG antibody (1 mg/ml, catalog no. sc-13585; Santa Cruz Biotechnology) was used as the detection antibody.
Immunoblot analysis
Cultured pancreatic cancer cells were lysed in ice-cold RIPA buffer (catalog no. 9806; Cell Signaling, Danvers, MA, USA) containing one tablet EDTA-free protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) for 10 min. For the detection of phospho-p44/42 and phospho-Smad2, we used a cell lysis buffer (catalog no. 9803; Cell Signaling). The western blot analysis was performed as previously described (Ketterer et al., 2009) . The following antibodies were used: mouse anti-ZAG (catalog no. sc-13585, 1:500; Santa Cruz Biotechnology), rabbit anti-phospho-p44/42 mitogen-activated protein kinase (Erk1/2) (Thr202/Tyr204; 1:1000, catalog no. 9101; Cell Signaling), rabbit anti-p21Waf1/Cip1 (12D1; 1:1000, catalog no. 2947; Cell Signaling), rabbit anti-phospho-Smad2 (Ser465/ 467;138D4; 1:1000, catalog no. 3108; Cell Signaling), rabbit anti-CDH1 (24E10; 1:5000, catalog no. 3195; Cell Signaling), mouse anti-VIM (SKU catalog no. 18-0052, 1:15000; Invitrogen, Carlsland, CA, USA), rabbit anti-HK2 (C64G5, 1:2000, catalog no. 2867; Cell signaling) or rabbit anti-GAPDH (1:5000; Santa Cruz Biotechnology) overnight at 4 1C.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitations were performed using the Magna ChIP A Chromatin Immunoprecipitation Kit (catalog no. 17-610; Millipore, Temecula, CA, USA) according to the manufacturer's instructions. Equal amounts of crosslinked chromatin from 1 Â 10 6 Panc-1 cells treated with TSA (1 mM) or DMSO for 2 h were precipitated with either 10 ml acetylated-H3 antibody or 10 ml normal rabbit IgG overnight. The total chromatin (1%) in each reaction was saved as an 'input' for later quantification. After purification, the enriched DNA was quantified by RT-PCR using primers specific for the ZAG promoter. The amount of immunoprecipitated DNA in each sample is represented as signal relative to input chromatin. Each yielded value was then normalized to control (DMSO treated). The assays were repeated three times. Sequences of primers are provided in Supplementary data section.
siRNA transfections Synthetic siRNA oligonucleotides for ZAG and negative control siRNA were purchased from Ambion (#s1848_1# and s1849_2#; Applied Biosystems, Darmstadt, Germany) and were prepared and stored according to the manufacturer's instructions. siRNA transfections were carried out according to the manufacturer's instructions. siPORT NeoFX Transfection Agent (Ambion Applied Biosystem, Austin, TX, USA) transfection reagent was used. The final concentration of both the control and specific oligonucleotides was 40 nM. The efficacy of the siRNA transfection was ascertained by immunoblot analysis after 48 h of transfection. Synthetic siRNA oligonucleotides for HK2 were obtained from Qiagen (catalog nos SI03021935_1# and SI00287329_2#, Qiagen, Hilden, Germany) and transfected with HiPerFect transfection reagent according to the manufacturer's instructions. The efficacy of HK2 downregulation was assessed after 72 h of transfection. The sequences of siRNA oligonucleotides are provided in Supplementary data section.
Proliferation assays
Cell growth was determined using the 3-(4,5-dimethylthiazole-2-yl)2,5-diphenyltetrazolium bromide (5 mg/ml in phosphatebuffered saline; Sigma-Aldrich) colorimetric growth assay as previously described (Zhang et al., 2007) . All assays were performed in triplicates and were repeated three times.
Invasion assays
To assess cell invasion in vitro, we used 24-well Matrigel invasion chambers with 8-mm pore sizes (BD Biosciences, San Jose, CA, USA) and reconstituted them with 600 ml serum-free Dulbecco's modified Eagle's medium in both the top and the bottom chambers for 2-4 h. Cells were trypsinized and were seeded into the top chamber at a density of 5 Â 10 4 cells (Aspc-1) or 1.25 Â 10 4 cells (Panc-1 and Su86.86) per well in 500 ml Dulbecco's modified Eagle's medium containing 0.5% fetal calf serum. The outer chambers contained 0.7 ml of medium (10% fetal calf serum). According to each experimental setup, TGF-b (CF111; Millipore) or rZAG was added to the top chambers at a dose of 10 ng/ml, 1 or 0.01 mg/ml. After incubation at 37 1C for 24 h, cells remaining attached to the upper surface of the membrane were carefully removed with cotton swabs, whereas cells that reached the underside of the chamber were stained with hematoxylin and eosin and were counted. All experiments were repeated three times.
Detection of EMT markers, phospho-ERK and p21
To analyze the effect of TGF-b and rZAG on EMT, we grew Panc-1 cells to 70% confluence in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. Cells were washed twice in serum-free medium and were starved for 24 h in serum-free medium, and were finally treated for 48 h with TGF-b (10 ng/ml) or carrier protein. rZAG was added at a concentration of 1 mg/ml, 90 min before the application of TGF-b. For Aspc-1, cells were (siRNA) transfected as described. At 24 h after transfection, the medium was removed and the cells were washed twice in serum-free medium and were starved for 12 h in serum-free medium. The cells were then treated for 36 h with TGF-b (10 ng/ml) or carrier protein.
For the endogenous TGF-b signaling blocking assay, SB525354 (200 nM), LY-364947 (25 mM) and PD98059 (50 mM, all from Tocris Bioscience, Bristol, UK) were used to treat Aspc-1 cells for 24 h in serum-free medium before RNA extraction. For the detection of phospho-ERK and p21, a similar experimental setup was carried out with the exception that TGF-b treatment was restricted to 24 h. All experiments were repeated three times.
RT-PCR pathway finder array
All the reagents and materials for the PCR array (PAHS-014) were purchased from SABiosciences (Frederick, MD, USA). The assay was performed according to the manufacturer's instruction. Data were analyzed using the web-based software from SABiosciences (http://www.sabiosciences.com/ pcr/arrayanalysis.php).
Statistical analysis
For statistical analyses, the GraphPad Prism 5 Software (GraphPad, San Diego, CA, USA) was used. The w 2 -test was used to compare the numbers of ZAG-positive samples between PanIN lesions, primary and metastatic PDAC, as well as the frequency of ZAG-positive samples in PETs, primary PDAC and ACCs. Unless otherwise stated, an unpaired t-test was used for group-wise comparisons. The level of statistical significance was set at Po0.05. Results are expressed as mean ± standard error of the mean (s.e.m.) unless indicated otherwise.
